A Phase I Study of the Hsp90 Inhibitor 17-DMAG (Alvespimycin) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), and B-cell Prolymphocytic Leukemia (B-PLL).

Trial Profile

A Phase I Study of the Hsp90 Inhibitor 17-DMAG (Alvespimycin) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), and B-cell Prolymphocytic Leukemia (B-PLL).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2015

At a glance

  • Drugs Alvespimycin (Primary)
  • Indications B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 15 Jan 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 30 Jan 2013 Planned End Date changed from 1 Jun 2012 to 1 Feb 2012 as reported by ClinicalTrials.gov.
    • 14 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top